DOPF is a designer drug from the substituted amphetamine family. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013. It has a binding affinity (Ki) of 9 nM at the serotonin receptor 5-HT2A but is not known to have been tested in humans.[1]
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H22FNO2 |
| Molar mass | 255.333 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
editReferences
edit- ^ Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion [Phenethylamine From structure to function] (in German). Nachtschatten Verlag AG. p. 778-780. ISBN 978-3-03788-700-4.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |